BioSpace News Archive

Omeros Corporation announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2020, which include:

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the quarter and nine months ended September 30, 2020, and provide

LENSAR, Inc., a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, announced financial results for the third quarter ended September 30, 2020 and provided an update on key strategic and operational initiatives.

Celcuity Inc., a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and expanded therapeutic options for cancer patients, announced financial results for the third quarter ended September 30, 2020 and summarized recent business progress.

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the third quarter ended September 30, 2020 and recent company developments. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, stated, “This has been a very exciting few months for TG especially sharing the first ever data from the UNITY-CLL Phase 3 trial last week showing that the trial met its primary endpoint of improvement in progression-

Company announces initiation of MultiStem ® Phase 2 study led by UTHealth in patients with trauma related inflammation and complications at Memorial Hermann-Texas Medical Center Management to host conference call at 4:30 pm EST today

Q3 2020 revenues of $15.2 million, Q3 2020 YTD revenues of $45.4 million DecisionDx-Melanoma report volume returned to quarterly year-over-year increase Q3 2020 gross margin of 84% Recently received final expanded positive Medicare coverage for DecisionDx-Melanoma

- Integrated analysis confirms addition of voclosporin to standard-of-care resulted in faster Renal Response compared to standard-of-care alone in lupus nephritis - - DDI study demonstrates no clinically meaningful interaction between voclosporin and MMF, supporting differentiation as a potential best-in-class CNI -

- U.S. Commercial Launch Preparations Underway Supporting the Tivozanib PDUFA Target Action Date of March 31, 2021 – - Ficlatuzumab Worldwide Rights Regained; Final Results from Open Label Randomized Phase 2 HNSCC Study and Plans for Pivotal Program Expected in the Middle of 2021 – - AV-380 IND Submission Expected by Year-end; Phase 1 Clinical Study Planned for the First Quarter of 2021 –

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting online, November 11-14, including poster presentations on November 11 th – 13 th . The comp